Evidence map›Paper›PMID 39812093›Full record

ReviewEuropean psychiatry : the journal of the Association of European Psychiatrists2025

International perspective on social cognition in schizophrenia: current stage and the next steps.

Silvia Corbera, Matthew M Kurtz, Amélie M Achim, Giulia Agostoni, Isabelle Amado, Michal Assaf, Stefano Barlati, Margherita Bechi, Roberto Cavallaro, Satoru Ikezawa and 7 more

Abstract readReview
In one paragraph

Review in European psychiatry : the journal of the Association of European Psychiatrists, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Starting from scratch: Ziermans et al. commentary.Schizophrenia research. Cognition · 2026
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Silvia CorberaDepartment of Psychological Science, Central Connecticut State University, New Britain, CT, USA.ORCID 0000-0002-5090-2462
Matthew M KurtzDepartment of Psychology, Wesleyan University, Middletown, CT, USA.
Amélie M AchimDepartement de psychiatrie and neurosciences, Université Laval, Canada.
Giulia AgostoniSchool of Psychology, Vita-Salute San Raffaele University, Milan, Italy.
Isabelle AmadoResource Centre in Ile de France for Cognitive Remediation and Psychosocial Rehabilitation (C3RP), GHU Paris Psychiatry Neurosciences, Paris, France.ORCID 0009-0009-6233-6582
Michal AssafOlin Neuropsychiatry Research Center, Hartford Hospital, Hartford, CT, USA.ORCID 0000-0001-5307-1986
Stefano BarlatiSchool of Medicine, University of Brescia, Brescia, Italy.ORCID 0000-0002-1784-3915
Margherita BechiDepartment of Clinical Neurosciences, IRCCS San Raffaele Hospital, Milan, Italy.
Roberto CavallaroSchool of Psychology, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0002-6877-1456
Satoru IkezawaDepartment of Psychiatry, International University of Health and Welfare Mita Hospital, Tokyo, Japan.ORCID 0000-0003-4712-9373
Hiroki OkanoDepartment of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0001-7583-2432
Ryo OkuboDepartment of Neuropsychiatry, National Hospital Organization, Obihiro Hospital, Obihiro, Japan.ORCID 0000-0002-1254-1926
Rafael PenadésHospital Clinic Barcelona, University of Barcelona, IDIBAPS, CIBERSAM, Spain.ORCID 0000-0002-1564-3717
Takashi UchinoFaculty of Medicine, Toho University, Tokyo, Japan.ORCID 0000-0001-5812-1727
Antonio VitaSchool of Medicine, University of Brescia, Brescia, Italy.
Yuji YamadaDepartment of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID 0000-0002-2169-1635
Morris D BellDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-0795-9196

Funding

The Social Brain in Schizophrenia and Autism Spectrum DisordersR01MH095888 · NIMH · HARTFORD HOSPITAL · PI ASSAF, MICHAL · 2012 to 2016
$2.6M
NIMH NIH HHS R01 MH095888
6 · The paper itself

Abstract

In the last decades, research from cognitive science, clinical psychology, psychiatry, and social neuroscience has provided mounting evidence that several social cognitive abilities are impaired in people with schizophrenia and contribute to functional difficulties and poor clinical outcomes. Social dysfunction is a hallmark of the illness, and yet, social cognition is seldom assessed in clinical practice or targeted for treatment. In this article, 17 international experts, from three different continents and six countries with expertise in social cognition and social neuroscience in schizophrenia, convened several meetings to provide clinicians with a summary of the most recent international research on social cognition evaluation and treatment in schizophrenia, and to lay out primary recommendations and procedures that can be integrated into their practice. Given that many extant measures used to assess social cognition have been developed in North America or Western Europe, this article is also a call for researchers and clinicians to validate instruments internationally and we provide preliminary guidance for the adaptation and use of social cognitive measures in clinical and research evaluations internationally. This effort will assist promoting scientific rigor, enhanced clinical practice, and will help propel international scientific research and collaboration and patient care.

Indexed as

Cognitive DysfunctionSchizophreniaSchizophrenic PsychologySocial CognitionHumansInternationalityclinical evaluationcross-cultural researchschizophreniasocial cognition

Identifiers

PMID39812093
PMCPMC11795453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.